Chinese biotech competition and the payer squeeze are reshaping European biotech
At BIO-Europe last week one preclinical company explained how it was building its drug development program with a focus on fitting prescribing and reimbursement models. This direction, the executive explained, was not selected because these models suited cancer interception, but instead because future partners in top pharma would need to be assured of the business […] The post Chinese biotech…
We haven't written up this one. Labiotech has the full story — the link below goes straight to it.